Skip to main content

Eli Lilly and Company

corporate_fare Company Profile

Eli Lilly and Company

LLY·NYSE·Life Sciences·CIK 0000059478

The company discovers, develops, manufactures, and markets human pharmaceutical products within a single business segment. It manufactures and distributes its products from facilities located in the United States, including Puerto Rico, as well as in Europe and Asia. The company sells its products in approximately 90 countries. Its product portfolio includes treatments across various therapeutic areas. In Cardiometabolic Health, products include Basaglar, a long-acting human insulin analog for diabetes, developed in collaboration with Boehringer Ingelheim. Other diabetes treatments are Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, and insulin lispro mix 75/25, which are human insulin analogs. Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 are human insulins of recombinant DNA origin for diabetes. Jardiance, also in collaboration with Boehringer Ingelheim, treats type 2 diabetes, reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, reduces the risk of cardiovascular death and hospitalizations for heart failure in adults, and reduces the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. Mounjaro is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist for adults with type 2 diabetes, used with diet and exercise to improve glycemic control. Trulicity treats type 2 diabetes in adults and pediatric patients 10 years and older, and reduces the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.

Eli Lilly and Company (NYSE:LLY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 161 items for LLY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for LLY spans 10-Q, 8-K.

Recent high-impact activity:

  • Mounjaro Wins Canadian Label Expansion for Cardiovascular Risk Reduction
  • Lilly Signs Up-to-$5.9B Oncology Licensing Deal With Stipple Bio
  • Lilly Pays $1.5B Cash for Private Biotech Calytrix Bio
  • Lilly's Oral GLP-1 Wins China Approval, First Pill in a Market Seen at $4.5B
  • China Approves Lilly's Oral Orforglipron; Hims Deal Adds Zepbound Access

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$65.18B
Net Income
$20.64B
Diluted EPS
$22.95
Op. Cash Flow
$16.81B
Gross Profit
$54.13B
Cash & Equivalents
$7.27B
Total Debt
$42.5B
Debt / Equity
1.60×
Net Margin
31.7%
Shares Outstanding
897.3M sh
Source: 10-K · filed 2026-02-12 · accession 0000059478-26-000013

Short Interest & Short Volume

2.66 days to cover

FINRA reported short interest of 7,213,927 shares in LLY as of the October 30, 2026 settlement, a 3.6% increase from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 35.8% of LLY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,213,927 shares as of October 30, 2026
Change vs prior period▲ 3.6%
Days to cover2.66 at avg daily volume of 2,709,288
Daily short volume (FINRA facilities)35.8% of 983,039 shares on November 20, 2026
5-day average short volume40.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$1348.06 +0.07% today
52-week range · as of 2026-10-29 $809.63 – $1408.38
Market cap
$1.27T
Volume
3.5M (1.2× avg)
3-mo avg 2.9M
Live data · 2026-11-21 20:07 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LLY - Latest Insights

LLY
Nov 18, 2026, 3:04 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,381.18
Real-time Price: $1,348.06 info
Change: -$33.12 (-2%) info
Market Cap: $1.267T info
LLY
Nov 17, 2026, 11:18 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,416.23
Real-time Price: $1,348.06 info
Change: -$68.17 (-5%) info
Market Cap: $1.267T info
LLY
Nov 16, 2026, 6:52 AM EST
Source: Reuters
Importance Score:
7
Updated Nov 16, 11:52 AM ET — Calytrix shareholders receive an upfront cash payment plus clinical and regulatory milestone payments; Calytrix's lead biparatopic antibody…
Price at Filing: $1,455.36
Real-time Price: $1,348.06 info
Change: -$107.30 (-7%) info
Market Cap: $1.267T info
LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,348.06 info
Change: -$104.64 (-7%) info
Market Cap: $1.267T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,348.06 info
Change: -$99.79 (-7%) info
Market Cap: $1.267T info
LLY
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1,411.12
Real-time Price: $1,348.06 info
Change: -$63.06 (-4%) info
Market Cap: $1.267T info
LLY
Nov 09, 2026, 10:23 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1,394.15
Real-time Price: $1,348.06 info
Change: -$46.09 (-3%) info
Market Cap: $1.267T info
LLY
Nov 06, 2026, 6:45 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,346.00
Real-time Price: $1,348.06 info
Change: +$2.06 (+0.15%) info
Market Cap: $1.267T info
LLY
Nov 04, 2026, 1:53 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,416.54
Real-time Price: $1,348.06 info
Change: -$68.48 (-5%) info
Market Cap: $1.267T info
LLY
Oct 29, 2026, 3:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1,368.10
Real-time Price: $1,348.06 info
Change: -$20.04 (-1%) info
Market Cap: $1.267T info
LLY
Oct 29, 2026, 12:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1,370.30
Real-time Price: $1,348.06 info
Change: -$22.24 (-2%) info
Market Cap: $1.267T info
LLY
Oct 29, 2026, 11:35 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1,363.50
Real-time Price: $1,348.06 info
Change: -$15.44 (-1%) info
Market Cap: $1.267T info
LLY
Oct 29, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1,344.00
Real-time Price: $1,348.06 info
Change: +$4.06 (+0.30%) info
Market Cap: $1.267T info
LLY
Oct 29, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1,345.00
Real-time Price: $1,348.06 info
Change: +$3.06 (+0.23%) info
Market Cap: $1.267T info
LLY
Oct 29, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1,315.60
Real-time Price: $1,348.06 info
Change: +$32.46 (+2%) info
Market Cap: $1.267T info
LLY
Oct 28, 2026, 6:45 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1,273.00
Real-time Price: $1,348.06 info
Change: +$75.06 (+6%) info
Market Cap: $1.267T info
LLY
Oct 26, 2026, 6:26 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1,282.11
Real-time Price: $1,348.06 info
Change: +$65.95 (+5%) info
Market Cap: $1.267T info
LLY
Oct 16, 2026, 6:06 AM EDT
Source: Reuters
Importance Score:
8
Updated Oct 16, 12:07 PM ET — Foundayo recommended for both type 2 diabetes and weight management, in film-coated tablets from 0.8 mg to 17.2 mg orforglipron; Lilly shar…
Price at Filing: $1,257.03
Real-time Price: $1,348.06 info
Change: +$91.03 (+7%) info
Market Cap: $1.267T info
LLY
Oct 05, 2026, 9:34 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $1,144.98
Real-time Price: $1,348.06 info
Change: +$203.08 (+18%) info
Market Cap: $1.267T info
LLY
Oct 02, 2026, 3:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $1,147.30
Real-time Price: $1,348.06 info
Change: +$200.76 (+17%) info
Market Cap: $1.267T info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets